Iridocorneal apposition after vitrectomy and gas injection.
Konishi
K I
KI
Department of Ophthalmology, School of Medicine, Fukuoka University, Japan. hhayashi@fukuoka-u.ac.jp
Kondo
H
H
Oshima
K
K
D000293:Adolescent; D000328:Adult; D000368:Aged; D003316:Corneal Diseases / Q000209:etiology* / Q000628:therapy; D003930:Diabetic Retinopathy / Q000601:surgery; D005260:Female; D005466:Fluorocarbons / Q000008:administration & dosage*; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure; D007499:Iris Diseases / Q000209:etiology* / Q000628:therapy; D007552:Isotonic Solutions / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013459:Sulfur Hexafluoride / Q000008:administration & dosage*; D000267:Tissue Adhesions; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014792:Visual Acuity; D014821:Vitrectomy / Q000009:adverse effects*; D018630:Vitreoretinopathy, Proliferative / Q000601:surgery
D005466:Fluorocarbons; D007552:Isotonic Solutions; C042852:perflutren; D010959:Tissue Plasminogen Activator; D013459:Sulfur Hexafluoride